A detailed history of Pinnacle Associates LTD transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Pinnacle Associates LTD holds 168,573 shares of SAGE stock, worth $965,923. This represents 0.02% of its overall portfolio holdings.

Number of Shares
168,573
Previous 293,251 42.52%
Holding current value
$965,923
Previous $3.18 Million 61.84%
% of portfolio
0.02%
Previous 0.05%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

SELL
$7.02 - $13.08 $875,239 - $1.63 Million
-124,678 Reduced 42.52%
168,573 $1.22 Million
Q2 2024

Jul 30, 2024

BUY
$10.58 - $17.9 $77,593 - $131,278
7,334 Added 2.57%
293,251 $3.18 Million
Q1 2024

Apr 26, 2024

BUY
$18.62 - $26.95 $2.18 Million - $3.16 Million
117,344 Added 69.61%
285,917 $5.36 Million
Q4 2023

Jan 19, 2024

SELL
$17.1 - $22.26 $127,292 - $165,703
-7,444 Reduced 4.23%
168,573 $3.65 Million
Q3 2023

Oct 23, 2023

SELL
$16.75 - $48.98 $100,014 - $292,459
-5,971 Reduced 3.28%
176,017 $3.62 Million
Q2 2023

Jul 26, 2023

SELL
$40.65 - $59.54 $203,128 - $297,521
-4,997 Reduced 2.67%
181,988 $8.56 Million
Q1 2023

May 04, 2023

BUY
$37.27 - $46.57 $566,653 - $708,050
15,204 Added 8.85%
186,985 $7.85 Million
Q4 2022

Jan 31, 2023

SELL
$32.2 - $43.61 $231,518 - $313,555
-7,190 Reduced 4.02%
171,781 $6.55 Million
Q4 2022

Jan 25, 2023

BUY
$32.2 - $43.61 $328,601 - $445,040
10,205 Added 6.05%
178,971 $0
Q3 2022

Oct 31, 2022

SELL
$32.28 - $43.27 $181,800 - $243,696
-5,632 Reduced 3.23%
168,766 $6.61 Million
Q2 2022

Aug 02, 2022

SELL
$27.52 - $37.99 $70,203 - $96,912
-2,551 Reduced 1.44%
174,398 $5.63 Million
Q1 2022

May 05, 2022

SELL
$30.71 - $45.71 $59,669 - $88,814
-1,943 Reduced 1.09%
176,949 $5.86 Million
Q4 2021

Feb 02, 2022

BUY
$37.06 - $47.11 $24,126 - $30,668
651 Added 0.37%
178,892 $7.61 Million
Q3 2021

Oct 19, 2021

BUY
$40.26 - $57.37 $4.04 Million - $5.75 Million
100,268 Added 128.59%
178,241 $7.9 Million
Q2 2021

Aug 02, 2021

BUY
$54.88 - $79.29 $53,123 - $76,752
968 Added 1.26%
77,973 $4.43 Million
Q1 2021

May 12, 2021

SELL
$70.65 - $96.76 $542,592 - $743,116
-7,680 Reduced 9.07%
77,005 $5.76 Million
Q4 2020

Jan 26, 2021

SELL
$58.41 - $89.06 $329,140 - $501,853
-5,635 Reduced 6.24%
84,685 $7.33 Million
Q3 2020

Oct 23, 2020

SELL
$41.13 - $62.45 $153,826 - $233,563
-3,740 Reduced 3.98%
90,320 $5.52 Million
Q2 2020

Aug 14, 2020

BUY
$25.95 - $43.15 $2.44 Million - $4.06 Million
94,060 New
94,060 $3.91 Million

Others Institutions Holding SAGE

About Sage Therapeutics, Inc.


  • Ticker SAGE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,422,300
  • Market Cap $340M
  • Description
  • Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...
More about SAGE
Track This Portfolio

Track Pinnacle Associates LTD Portfolio

Follow Pinnacle Associates LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pinnacle Associates LTD, based on Form 13F filings with the SEC.

News

Stay updated on Pinnacle Associates LTD with notifications on news.